Covaxin for Children: Study says robust safety, immunogenicity in 2-18 year old…
Bharat Biotech had conducted phase II/III, open-label, and multicenter studies to evaluate the safety, reactogenicity, and immunogenicity of Covaxin in healthy children and adolescents in…